And again, even that, you're talking in the heyday, maybe $2 billion for the whole industry, right
In adults with obesity and knee osteoarthritis, retatrutide delivered: 9mg dose: 26.4% body weight reduction at 68 weeks 12mg dose: 28.7% body weight reduction at 68 weeks (average of 71.2 pounds lost) Placebo: 2.1% body weight reduction The 68-week timeframe is longer than the Phase 2 trial, which partially explains the higher numbers
As the American Journal of Managed Care noted: "If Congress has not acted by the time the Bridge expires, patients who have been on these medications for a year and a half face an abrupt coverage cliff." What Changed and Why It Matters Now The program was announced months ago, but the funding-cliff question becomes practically urgent only when seniors are actively enrolling and taking their first doses which is now
GLP-1 receptor agonists have demonstrated robust clinical efficacy in reducing blood glucose levels, lowering HbA1c, and supporting meaningful weight loss
if you are still in the titration phase or on a subtherapeutic maintenance dose, increasing to the next level often restarts weight loss
